Repligen agreed on 22 July to acquire BioLife Solutions, a Bothell, Washington-based supplier of cell processing tools, in a cash-and-stock deal with an enterprise value of about $1.5bn.
Why Repligen Corporation is buying BioLife Solutions, Inc.
Repligen said BioLife adds a high-margin, recurring consumables business in the fast-growing cell therapy market. BioLife's CryoStor biopreservation media support 18 commercially approved therapies and most US commercially sponsored cell-based therapy trials, while Repligen brings wider global reach, including Asia-Pacific.
“The acquisition of BioLife represents a natural next step in the evolution of our strategy”
Deal terms and financing
BioLife holders received $11.25 in cash and 0.1442 Repligen shares for each share, worth $31.00 at signing, a 24% premium to the 90-day VWAP. The cash was funded from Repligen's balance sheet. Repligen expects the deal to add at least 5 cents to adjusted EPS in year one and 25 cents in year two.
Regulatory approvals and timing
BioLife's special meeting to adopt the merger agreement was held on 5 October 2026, and Repligen announced completion on 6 October.
Market context
BioLife expected second-quarter 2026 revenue of $28.5m, up 21% year on year, after repositioning around its biopreservation franchise.
